AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12575552 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril
Number of subjects: 292
Study 9197517 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistaminergic intervention (pheniramine)
Number of subjects: 10
Study 9197517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9197517 — intervention group
Group type: EXPERIMENTAL
Intervention: Brainstem auditory evoked potentials (BAEPs) in Down syndrome subjects
Number of subjects: 10
Study 9197517 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory event-related potentials (ERPs) in Down syndrome subjects
Number of subjects: 10
Study 8162926 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 (5% or 8% in O2)
Number of subjects: 0
Study 8162926 — intervention group
Group type: COMPARATOR
Intervention: 100% O2
Number of subjects: 0
Study 8162926 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (0.8 mg)
Number of subjects: 0
Study 8162926 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (0.1 mg)
Number of subjects: 0
Study 8162926 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 0
Study 8162926 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2
Number of subjects: 0
Study 3166951 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine at 10(‐9)M
Number of subjects: 68
Study 31179316 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower level of education
Number of subjects: 204
Study 31179316 — intervention group
Group type: EXPERIMENTAL
Intervention: Not practicing at least 30 min daily walks
Number of subjects: 204
Study 31179316 — intervention group
Group type: EXPERIMENTAL
Intervention: Not exercising routinely
Number of subjects: 204
Study 31179316 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 204
Study 27296456 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral GON block with bupivacaine 0.5%
Number of subjects: 36
Study 27296456 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure with normal saline
Number of subjects: 36
Study 26531277 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal parathyroidectomy (SPTX)
Number of subjects: 63
Study 26531277 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parathyroidectomy (TPTX)
Number of subjects: 63
Study 26531277 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parathyroidectomy and autotransplantation (TPTX+AT)
Number of subjects: 63
Study 23683134 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 2269
Study 23683134 — intervention group
Group type: COMPARATOR
Intervention: Febuxostat 40 mg
Number of subjects: 2269
Study 23683134 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (200 mg or 300 mg)
Number of subjects: 2269
Study 20052661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage
Number of subjects: 208
Study 20052661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage for CL < or = 5.9 mm
Number of subjects: 208
Study 20052661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage for CL < or = 15.9 mm
Number of subjects: 208
Study 20052661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage for CL 16-24.9 mm
Number of subjects: 208
Study 20052661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage for CL < 25 mm
Number of subjects: 208
Study 20052661 — intervention group
Group type: COMPARATOR
Intervention: No cerclage
Number of subjects: 208
Study 17997711 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/d orally for 3 years
Number of subjects: 1431
Study 15977211 — intervention group
Group type: EXPERIMENTAL
Intervention: F-18 fluorodeoxy-D-glucose-positron emission tomography (FDG-PET) scanning
Number of subjects: 144
Study 12681994 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MRI before and 6 weeks after catheter ablation
Number of subjects: 28
Study 12681994 — intervention group
Group type: COMPARATOR
Intervention: Control group (27 patients)
Number of subjects: 28
Study 11065222 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 30
Study 11065222 — intervention group
Group type: COMPARATOR
Intervention: American Heart Association step 1 diet
Number of subjects: 30
Study 8900554 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 8843
Study 8900554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8843
Study 8900554 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol in patients with a history of peptic ulcer disease
Number of subjects: 8843
Study 8900554 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol in patients with a history of previous GI bleeding
Number of subjects: 8843
Study 8900554 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol in patients with significant cardiovascular disease
Number of subjects: 8843
Study 8900554 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol in patients with significant functional disability
Number of subjects: 8843
Study 8900554 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol in patients requiring concomitant antacid use
Number of subjects: 8843
Study 1800188 — intervention group
Group type: EXPERIMENTAL
Intervention: Celandin-aloevera-psyllium preparation
Number of subjects: 35
Study 1800188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 6409521 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 41
Study 6409521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 31971679 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for subsequent infusions, administered intravenously every 3 weeks for 21 weeks)
Number of subjects: 83
Study 31971679 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprotumumab
Number of subjects: 83
Study 31971679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 31516055 — intervention group
Group type: EXPERIMENTAL
Intervention: BKPro‐Cyan
Number of subjects: 90
Study 31516055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 30088420 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric with Bioperine (n = 6)
Number of subjects: 14
Study 30088420 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin with Bioperine (n = 5)
Number of subjects: 14
Study 30088420 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 3)
Number of subjects: 14
Study 26847728 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-loading at rest
Number of subjects: 18
Study 26847728 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-loading following exercise
Number of subjects: 18
Study 26847728 — intervention group
Group type: EXPERIMENTAL
Intervention: D-glucose (10 mmol L(-1))
Number of subjects: 18
Study 26847728 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 18
Study 26847728 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 18
Study 25707083 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP) activated by LED/laser light
Number of subjects: 112
Study 25707083 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP) without LED/laser light activation
Number of subjects: 112
Study 25707083 — intervention group
Group type: COMPARATOR
Intervention: Control group (no restoration)
Number of subjects: 112
Study 25707083 — intervention group
Group type: EXPERIMENTAL
Intervention: Shallow restoration
Number of subjects: 112
Study 25707083 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep restoration
Number of subjects: 112
Study 22431338 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole at 0.5 μm
Number of subjects: 0
Study 22431338 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole treatment for 1 week
Number of subjects: 0
Study 20094001 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-page abbreviated teaching tool (ATT) summarizing CDC guidelines
Number of subjects: 237
Study 20094001 — intervention group
Group type: COMPARATOR
Intervention: weblink to CDC sexually transmitted disease treatment guidelines
Number of subjects: 237
Study 17284546 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise
Number of subjects: 20
Study 17284546 — intervention group
Group type: COMPARATOR
Intervention: Passive modalities
Number of subjects: 20
Study 15595937 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) therapy
Number of subjects: 251
Study 15595937 — intervention group
Group type: COMPARATOR
Intervention: Glatiramer acetate (GA) therapy after placebo delay
Number of subjects: 251
Study 11875352 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed faking (subjects given additional information about computed dynamic posturography)
Number of subjects: 60
Study 11875352 — intervention group
Group type: COMPARATOR
Intervention: Naïve subjects (no additional information provided)
Number of subjects: 60
Study 10588611 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled allergen challenge
Number of subjects: 11
Study 10588611 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids pretreatment
Number of subjects: 11
Study 7826294 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg/d)
Number of subjects: 3711
Study 7826294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3711
Study 2108408 — intervention group
Group type: EXPERIMENTAL
Intervention: L-649,923 (oral LTD4 antagonist)
Number of subjects: 12
Study 2108408 — intervention group
Group type: COMPARATOR
Intervention: Placebo (diluent challenge)
Number of subjects: 12
Study 6765920 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (10-30 mg twice daily)
Number of subjects: 23
Study 31368759 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraverted behavior for 1 week
Number of subjects: 0
Study 31368759 — intervention group
Group type: COMPARATOR
Intervention: Introverted behavior for 1 week
Number of subjects: 0
Study 31297997 — intervention group
Group type: EXPERIMENTAL
Intervention: Microendoscope-assisted MIS-TLIF
Number of subjects: 53
Study 31297997 — intervention group
Group type: COMPARATOR
Intervention: Conventional tubular retractor-assisted MIS-TLIF
Number of subjects: 53
Study 31297997 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study 28403379 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 125 mg/d
Number of subjects: 66
Study 28403379 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 500 mg/d
Number of subjects: 66
Study 28403379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 26044566 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol 200 mg/day
Number of subjects: 1600
Study 26044566 — intervention group
Group type: EXPERIMENTAL
Intervention: probucol 500 mg/day
Number of subjects: 1600
Study 26044566 — intervention group
Group type: COMPARATOR
Intervention: aspirin 100 mg/day
Number of subjects: 1600
Study 26044566 — intervention group
Group type: COMPARATOR
Intervention: non-probucol
Number of subjects: 1600
Study 24007755 — intervention group
Group type: EXPERIMENTAL
Intervention: Keeping Baby Safe In and Around the Car DVD
Number of subjects: 195
Study 24007755 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 195
Study 21807446 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic PFE-planning
Number of subjects: 112
Study 21807446 — intervention group
Group type: COMPARATOR
Intervention: Active control conditions
Number of subjects: 112
Study 21807446 — intervention group
Group type: COMPARATOR
Intervention: Negative control from partners (in control groups)
Number of subjects: 112
Study 21807446 — intervention group
Group type: COMPARATOR
Intervention: Individual action control
Number of subjects: 112
Study 21807446 — intervention group
Group type: COMPARATOR
Intervention: Action control (longitudinally)
Number of subjects: 112
Study 18757056 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 or 30mg/day)
Number of subjects: 61
Study 18757056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 16781624 — intervention group
Group type: EXPERIMENTAL
Intervention: Engystol-based therapy
Number of subjects: 397
Study 16781624 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapies (antihistamines, antitussives, NSAIDs)
Number of subjects: 397
Study 12750578 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated Eating Disorder Inventory (EDI) score (highest quartile)
Number of subjects: 91
Study 12750578 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligo/amenorrhea
Number of subjects: 91
Study 12750578 — intervention group
Group type: EXPERIMENTAL
Intervention: Eumenorrheic runners with elevated EDI scores
Number of subjects: 91
Study 12750578 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated EDI score and oligo/amenorrhea
Number of subjects: 91
Study 10722768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg once daily
Number of subjects: 288
Study 10722768 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium 40 microg four times daily
Number of subjects: 288
Study 9187981 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-managed, home-based, multifactorial risk-reduction program
Number of subjects: 585
Study 9187981 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 585
Study 8465732 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon mitral valvotomy (BMV)
Number of subjects: 200
Study 8465732 — intervention group
Group type: COMPARATOR
Intervention: Surgical closed mitral valvotomy (CMV)
Number of subjects: 200
Study 3798420 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen therapy
Number of subjects: 20
Study 3798420 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 20
Study 29036554 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwire assisted technique
Number of subjects: 212
Study 29036554 — intervention group
Group type: COMPARATOR
Intervention: Contrast venography guided technique
Number of subjects: 212
Study 27983686 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg polyphenols derived from red wine and grape extracts in protein-rich beverages (dairy, soy)
Number of subjects: 35
Study 27983686 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg polyphenols derived from red wine and grape extracts in protein-free beverage
Number of subjects: 35
Study 27983686 — intervention group
Group type: COMPARATOR
Intervention: Placebo (six gelatine capsules)
Number of subjects: 35
Study 24965310 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese subjects in fasting state
Number of subjects: 58
Study 24965310 — intervention group
Group type: COMPARATOR
Intervention: Lean subjects in fasting state
Number of subjects: 58
Study 24965310 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese subjects after food intake
Number of subjects: 58
Study 22852210 — intervention group
Group type: EXPERIMENTAL
Intervention: Contra-lateral needling
Number of subjects: 106
Study 22852210 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 106
Study 22852210 — intervention group
Group type: COMPARATOR
Intervention: Non-acupuncture
Number of subjects: 106
Study 20434015 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 0
Study 20434015 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18285548 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir 100 mg twice daily
Number of subjects: 111
Study 18285548 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir 400 mg once daily
Number of subjects: 111
Study 18285548 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir 400 mg twice daily
Number of subjects: 111
Study 18285548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 18285548 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir
Number of subjects: 111
Study 16173886 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol cues
Number of subjects: 134
Study 16173886 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol cues with unavailability information
Number of subjects: 134
Study 16173886 — intervention group
Group type: COMPARATOR
Intervention: Neutral cues
Number of subjects: 134
Study 16173886 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol cues with availability information
Number of subjects: 134
Study 15624040 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg/day (n = 30)
Number of subjects: 43
Study 15624040 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 43
Study 11715353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg/day
Number of subjects: 732
Study 11715353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg/day
Number of subjects: 732
Study 11715353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 732
Study 11715353 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU/day
Number of subjects: 732
Study 9143445 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a lesion in the occipitotemporal cortex, superior temporal cortex, and frontal cortex
Number of subjects: 23
Study 9143445 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with damage in the anterior inferotemporal cortex
Number of subjects: 23
Study 9143445 — intervention group
Group type: COMPARATOR
Intervention: Age-matched volunteers
Number of subjects: 23
Study 7989424 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 0
Study 7989424 — intervention group
Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 0
Study 3619222 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil during low-sodium diet (9 meq/d)
Number of subjects: 13
Study 3619222 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil during high-sodium diet (212 meq/d)
Number of subjects: 13
Study 29153754 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined activity program (90-minute sessions weekly for 40 weeks)
Number of subjects: 308
Study 29153754 — intervention group
Group type: COMPARATOR
Intervention: Health education program (90-minute classes thrice during the 40-week trial)
Number of subjects: 308
Study 28334708 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Number of subjects: 10
Study 28334708 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 10
Study 25302753 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care follow-up
Number of subjects: 189
Study 25302753 — intervention group
Group type: COMPARATOR
Intervention: HF clinic follow-up
Number of subjects: 189
Study 23866725 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Number of subjects: 34
Study 23866725 — intervention group
Group type: COMPARATOR
Intervention: Rest in bed (Control)
Number of subjects: 34
Study 21876572 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml/kg of 0.25 % bupivacaine with 1 mg/kg of tramadol (Group B)
Number of subjects: 40
Study 21876572 — intervention group
Group type: COMPARATOR
Intervention: 0.5 ml/kg of 0.25 % bupivacaine (Group A)
Number of subjects: 40
Study 19015485 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-677 25 mg
Number of subjects: 563
Study 19015485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563
Study 16731091 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected black women who received CDC recommended treatment
Number of subjects: 1038
Study 16731091 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected black women
Number of subjects: 1038
Study 16731091 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of bacterial vaginosis, T vaginalis, or C trachomatis
Number of subjects: 1038
Study 16731091 — intervention group
Group type: COMPARATOR
Intervention: Uninfected black women
Number of subjects: 1038
Study 12730989 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral GPi pallidotomy
Number of subjects: 36
Study 12730989 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 36
Study 11049909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 11049909 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 5 microg/kg (small-dose)
Number of subjects: 75
Study 11049909 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 10 microg/kg (large-dose)
Number of subjects: 75
Study 8615503 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine 12 mg
Number of subjects: 6
Study 8615503 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 150 micrograms
Number of subjects: 6
Study 1397667 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivida (500 mg/day for 90 days)
Number of subjects: 30
Study 1397667 — intervention group
Group type: COMPARATOR
Intervention: Imedeen (380 mg/day for 90 days)
Number of subjects: 30
Study 3898418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 20 mg
Number of subjects: 60
Study 3898418 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 100 mg
Number of subjects: 60
Study 30282398 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal approach
Number of subjects: 60
Study 30282398 — intervention group
Group type: EXPERIMENTAL
Intervention: S1 foraminal approach
Number of subjects: 60
Study 30282398 — intervention group
Group type: EXPERIMENTAL
Intervention: L5-S1 transforaminal approach
Number of subjects: 60
Study 30282398 — intervention group
Group type: COMPARATOR
Intervention: All groups (caudal, S1 foraminal, L5-S1 transforaminal)
Number of subjects: 60
Study 26996246 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS up-titration from 30 mg to 60 mg
Number of subjects: 362
Study 26996246 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan up-titration from 80 mg to 160 mg
Number of subjects: 362
Study 26996246 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combination of Nifedipine GITS (30 mg) and Valsartan (80 mg)
Number of subjects: 362
Study 26996246 — intervention group
Group type: COMPARATOR
Intervention: Low-dose monotherapy of Nifedipine GITS (30 mg)
Number of subjects: 362
Study 26996246 — intervention group
Group type: COMPARATOR
Intervention: Low-dose monotherapy of Valsartan (80 mg)
Number of subjects: 362